Anti-heparin interference leucine aminopeptidase measuring reagent
A technology of leucine aminopeptidase and anti-interference agent, which is applied in the field of medical testing, can solve the problems of not being able to meet the clinical requirements for rapid return of test results, the time required for serum separation, and the false increase of test results, etc., to achieve good anti-interference. The effect of heparin interference performance, meeting the clinical test requirements, and good stability
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2013-01-09
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of medical testing, in particular to a heparin-resistant leucine aminopeptidase assay reagent. Background technique
[0002] Leucine aminopeptidase (Leucine aminopeptidase, LAP, EC 3.4.11.1) is a proteolytic enzyme that can hydrolyze the N-terminal of the peptide chain and form peptide bonds from leucine and other amino acids. It is widely distributed in the liver and pancreas. , kidney and other tissues. When human liver, gallbladder, pancreas and other tissues have lesions, the level of serum LAP can increase. Determination of serum leucine aminotranspeptidase can be used as another indicator for the diagnosis of liver diseases, and it is valuable for the differential diagnosis of cholestatic hepatitis, hepatic obstruction and pancreatic cancer. Unlike other liver function enzymes, which can only be tested in blood samples, LAP can also be tested in urine. In some cases it is possible to detect changes ...
Examples
Embodiment 1
[0023] Reagent 1:
[0024] Tris hydroxymethyl amino buffer (pH 7.0) 50mmol / L
[0025] Tween 20 5ml / L
[0027] Reagent 2:
[0028] 2-Morpholineethanesulfonic acid buffer (pH 4.0) 100mmol / L
[0029] L-leucyl-p-nitroanilide 2mmol / L
[0030] Sucrose 5g / L
[0032] Reagent 1 and Reagent 2 can be in dry powder state and used after adding water to dissolve before use; they can also be made into liquid reagents and used directly;
Embodiment 2
[0034] Reagent 1:
[0035] N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid buffer (pH 8.0) 100mmol / L
[0036] Span-80 10ml / L
[0037] Potassium sorbate 1g / L;
[0038] Reagent 2:
[0039] Acetic acid-sodium acetate buffer (pH 3.0) 100mmol / L
[0040] L-leucyl-p-nitroanilide 5mmol / L
[0041] BSA 2g / L
[0043] Reagent 1 and Reagent 2 can be in dry powder state and used after adding water to dissolve before use; they can also be made into liquid reagents and used directly;
Embodiment 3
[0045] Reagent 1:
[0046] N-(2-hydroxyethyl)piperazine-N'-4-butanesulfonic acid buffer (pH 8.5) 500mmol / L
[0047] Triton X-100 20ml / L
[0048] Proclin300 1g / L;
[0049] Reagent 2:
[0050] Imidazole buffer (pH 6.0) 100mmol / L
[0051] L-leucyl-p-nitroanilide 20mmol / L
[0052] Sorbitol 5g / L
[0053] Proclin300 0.1g / L.
[0054] Reagent 1 and Reagent 2 can be in dry powder state and used after adding water to dissolve before use; they can also be made into liquid reagents and used directly;
[0055] The testing conditions for the kit of the present invention to measure LAP in samples are as follows: temperature: 30-37° C.; light path of cuvette: 1.0 cm. The main detection wavelength is 405nm.
[0056] The method of using the LAP determination kit of the present invention to measure LAP in the sample is as follows: add R1 to the sample (calibration tube as the sample) and mix evenly, after incubating at 30-37°C for 3-5min, immediately add R2 to mix evenly, and then add R2...